Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis | Synapse
March 3, 2026
Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis
Puntos clave
Disitamab vedotin treatment reports improved efficacy in HER2-negative and HER2-low urothelial carcinoma patients, signaling a potential shift in treatment protocols.
The analysis includes data from multiple studies that affirm the effectiveness of disitamab vedotin, showing a significant therapeutic benefit.
Systematic review and meta-analysis assessed HER2 expression levels in locally advanced or metastatic urothelial carcinoma cases across various datasets and populations.
Results support integrating disitamab vedotin in clinical practice for treating specific forms of urothelial carcinoma, though broader validation is warranted.